Atrium Medical’s covered versus balloon expandable stent trial (COBEST) demonstrated positive results of Atrium’s proprietary balloon expandable covered stent technology over traditional bare metal stents (BMS) for the treatment of peripheral arterial disease (PAD).
An independent landmark prospective multicentre randomised controlled COBEST trial showed that patients implanted with Atrium’s Advanta V12 were more likely to remain free from binary restenosis and have fewer reinterventions than patients implanted with BMS.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Advanta Vascular V12 covered stent is a low profile, pre-mounted covered stent made of a radial expandable stainless steel that is completely encapsulated with Atrium’s patented one-piece covering technology.
The trial showed Vascular V12 produced lower restenosis rates, target vessel revascularization (TVR) rates, improved ABI’s, long term patency and clinical outcomes compared to BMS.
Royal Perth Hospital in Perth, Australia, head of vascular surgery Mwipatayi said the striking result from the COBEST study was the five-times lower TVR rate with Atrium’s V12 when compared to BMS.
Atrium’s Vascular V12 showed benefit in patients with more complex disease (TASC C & D lesions).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
